Closed
The Marked Chart Wire · Health
Valneva
Valneva reported that its S4V2 immunization achieved its main goal in a phase 2 study, significantly lowering infection rates compared to a placebo. A separate infant study also showed positive safety data.
New to this? Read: Reading a stock chart
Lupus Drug
UCB and Biogen say their lupus treatment dapirolizumab pegol achieved higher response rates than placebo in post-hoc analyses of phase 3 trial data.
Mineralys Therapeutics
Mineralys Therapeutics said lorundrostat lowered systolic blood pressure by 17.8 mmHg at week 48 in a phase 3 trial extension. About 56 percent of patients reached levels below 130 mmHg.
FDA Approval
The FDA has approved daraxonrasib from Revolution Medicines for the treatment of pancreatic cancer.
Evaxion
The biotech firm disclosed new Phase 2 findings for its personalized vaccine, EVX-01. The data indicated robust immune reactions and validated its AI-Immunology platform.
Novartis
Novartis is said to be discontinuing a heart medication developed with Ionis following a late-stage clinical trial failure.
J&J Psoriasis Drug
Johnson & Johnson announced positive results from a late-stage trial of its oral medication for plaque psoriasis and psoriatic arthritis.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.